Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.79+0.09 (+0.61%)
Close on Nov 17, 2026Market cap $12.34BP/E 27.1Yield 0.57%
Dr Reddys Laboratories price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Dr Reddys Laboratories's price to sales ratio was 3.5× on Nov 11, 2026, against 3.2× a year earlier. Over the last 5 years it ranged from 2.8× to 4.3×, with a median of 3.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.5× | +0.2 |
| 2025 | Dec 31, 2025 | 3.2× | −0.8 |
| 2024 | Dec 31, 2024 | 4.0× | +0.1 |
| 2023 | Dec 29, 2023 | 3.9× | +0.6 |
| 2022 | Dec 30, 2022 | 3.3× | −0.9 |
| 2021 | Dec 31, 2021 | 4.3× | −0.7 |
| 2020 | Dec 31, 2020 | 4.9× | +1.8 |
| 2019 | Dec 31, 2019 | 3.1× | +0.1 |
| 2018 | Dec 31, 2018 | 3.1× | +0.2 |
| 2017 | Dec 29, 2017 | 2.9× | −0.5 |
| 2016 | Dec 30, 2016 | 3.4× | – |
See a number that looks wrong?